As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

At a time when CRISPR companies have struggled, the Feng Zhang spinoff Arbor Biotechnologies gets a cash infusion to head to clinical trials.

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of ...

Arbor Biotechnologies has closed $73.9m in a Series C financing round, earmarked for advancing its gene editing therapeutic ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

“Arbor is developing a differentiated portfolio with first-in-class potential to deliver on the promise of CRISPR-based genetic medicines,” said Keith Crandell, co-founder and partner at ARCH ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

The company is progressing gene editing medicine through a multi-centre, open-label, Phase I/II trial. Credit: metamorworks/Shutterstock. Arbor Biotechnologies has ...

Texas is officially stepping into a new era. The post Texas Insider Confirms Ryan Wingo's Availability Status as Fresh ...